Liver Disease Treatment Market Set for Exponential Growth: Projections Show $36.45 Bn by 2031 with Remarkable 5.7% CAGR

PORTLAND, OREGON, UNITED STATES, July 10, 2024 /EINPresswire.com/ -- As per the report, the global liver disease treatment industry generated $20.67 billion in 2020, and is projected to garner $36.45 billion by 2030, growing at a CAGR of 5.7% from 2021 to 2030.

Key Takeaways:

The antiviral drugs segment held the lion’s share
The cancer segment to portray the highest CAGR through 2030
North America held the largest share

Furthermore, immunoglobulin is used in treatment of certain types of hepatitis. Moreover, vaccines are used to prevent hepatitis viral infection. For instance, vaccines are available for prevention of hepatitis A, B, and C. Furthermore, other products such as corticosteroids are used in the treatment of liver related autoimmune diseases such as autoimmune hepatitis. Thus, there are various liver related conditions such as hepatitis, autoimmune diseases, non-alcoholic fatty liver, cancer, and genetic disorders, which are treated by using different types of products such as anti-viral drugs, immunosuppressants, vaccines immunoglobulins, corticosteroids, targeted therapy, and chemotherapy.

Get Sample Report at: https://www.alliedmarketresearch.com/request-sample/388

Increase in incidence of liver diseases, surge in government and non-government awareness program, and surge in geriatric population coupled with rise in alcohol consumption and poor dietary habits have boosted the growth of the global liver disease treatment market. However, strict regulatory approvals related to liver diseases treatment drugs and vaccines and resistance to antiviral drugs used in treatment of hepatitis B and C hamper the market growth. On the contrary, presence of strong pipeline products is expected to open new opportunities for the market players in the future.

Market Segmentation:

By TREATMENT TYPE:
Antiviral Drugs
Immunosuppressants
Vaccines
Immunoglobulins
Corticosteroids
Targeted Therapy
Chemotherapy

By DISEASE TYPE:
Hepatitis
Autoimmune Diseases
Non-alcoholic Fatty Liver Disease (NAFLD)
Cancer
Genetic Disorders
Others

By Region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, Spain, Rest of Europe)
Asia-Pacific (Japan, China, India, Australia, South Korea, Rest of Asia-Pacific)
LAMEA (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)

Covid-19 scenario:

The Covid-19 outbreak has a moderate impact due to decline in need for drugs that are used in liver treatment, limited availability of medical care, and shortage of healthcare staff.

The rise in burden of Covid-19 related hospitalization negatively affected the healthcare sector.

On the contrary, the research studies and activities such as clinical trials for safety and efficacy for treatment of liver diseases boosted the demand for liver disease treatment.

Request for Customization: https://www.alliedmarketresearch.com/request-for-customization/388

Regional Growth Dynamics:

By region, the market across North America held the largest share in 2020, accounting for more than two-fifths of the market, due to rise in geriatric population, adoption of advanced technologies, robust R&D infrastructure for life science researchers, and improved liver disease treatment. However, the global liver disease treatment market across Asia-Pacific is expected to manifest the highest CAGR of 7.8% during the forecast period, owing to rise in liver diseases, increase in public-private investments, and government support for pharmaceutical and biotechnology R&D.

Major market players:

AbbVie Inc.
Astellas Pharma Inc.
Abbott Laboratories
Eli Lilly and Company
Bristol Myers Squibb
Emergent BioSolutions (Cangene bioPharma)
F. Hoffman-LA Roche
Merck & Co., Inc. (Merck Sharp & Dohme Corp.)
Gilead Sciences, Inc.
Viatris Inc.

Buy this Premium Research Report: https://www.alliedmarketresearch.com/purchase-enquiry/388

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa
Allied Market Research
+1 800-792-5285
email us here
Visit us on social media:
Facebook
X